Actinium Pharmaceuticals, Inc. (Delaware) Common Stock (NY:ATNM)

1.310 +0.040 (+3.15%)
Official Closing Price Updated: 8:00 PM EDT, Apr 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 324,480
Open 1.230
Bid (Size) 1.250 (75)
Ask (Size) 1.270 (1)
Prev. Close 1.270
Today's Range 1.210 - 1.360
52wk Range 1.029 - 10.24
Shares Outstanding 21,331,314
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ROSEN, A LEADING LAW FIRM, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ATNM
From The Rosen Law Firm PA
Via GlobeNewswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium
From Faruqi & Faruqi LLP
Via GlobeNewswire

Performance

YTD
+4.0%
+4.0%
1 Month
-29.9%
-29.9%
3 Month
+1.6%
+1.6%
6 Month
-22.0%
-22.0%
1 Year
-80.0%
-80.0%

More News

Read More
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Solaris, Actinium, Bakkt, and Cerevel and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium
From Faruqi & Faruqi LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM
From Pomerantz LLP
Via GlobeNewswire
ATNM Investors Have the Opportunity to Lead the Actinium Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
From Faruqi & Faruqi LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Solaris, Actinium, Bakkt, and Cerevel and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ATNM Investors Have the Opportunity to Lead the Actinium Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
From Faruqi & Faruqi LLP
Via GlobeNewswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium
From Faruqi & Faruqi LLP
Via GlobeNewswire
Shareholder Alert: Scott+Scott Attorneys at Law LLP Issues Corrected Notice to Clarify Deadline To Seek Appointment As Lead Plaintiff In Securities Class Action Against Actinium Pharmaceuticals, Inc. (NYSE American: ATNM)
From Scott+Scott Attorneys at Law LLP
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM
From Pomerantz LLP
Via GlobeNewswire
ATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Actinium Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
ACTINIUM ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Actinium Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Securities Fraud Investigation Into Actinium Pharmaceuticals, Inc. (ATNM) Announced – Investors Who Lost Money Urged to Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay & Murray LLP
Via Business Wire
Actinium Pharmaceuticals, Inc. (ATNM) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM
From Pomerantz LLP
Via GlobeNewswire
Rosen Law Firm Urges Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
Securities Fraud Investigation Into Actinium Pharmaceuticals, Inc. (ATNM) Announced – Investors Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz
From Law Offices of Frank R. Cruz
Via Business Wire
ATNM Investors Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Scott+Scott Attorneys at Law LLP Files Securities Class Action Against Actinium Pharmaceuticals, Inc. (NYSE American: ATNM)
From Scott+Scott Attorneys at Law LLP
Via Business Wire
Global Radiotherapy Market Expected to Reach $9.62 Billion By 2030 Realizing Growth Due to Technological Advancements
Via FinancialNewsMedia
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Top movers in Wednesday's pre-market session
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session.
Via Chartmill
Regencell, GlucoTrack, TC Biopharm, AbbVie, Actinium: 5 Health Care Stocks That Lit Up Retail Discussions Last Week
Via Stocktwits

Frequently Asked Questions

Is Actinium Pharmaceuticals, Inc. (Delaware) Common Stock publicly traded?
Yes, Actinium Pharmaceuticals, Inc. (Delaware) Common Stock is publicly traded.
What exchange does Actinium Pharmaceuticals, Inc. (Delaware) Common Stock trade on?
Actinium Pharmaceuticals, Inc. (Delaware) Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Actinium Pharmaceuticals, Inc. (Delaware) Common Stock?
The ticker symbol for Actinium Pharmaceuticals, Inc. (Delaware) Common Stock is ATNM on the New York Stock Exchange
What is the current price of Actinium Pharmaceuticals, Inc. (Delaware) Common Stock?
The current price of Actinium Pharmaceuticals, Inc. (Delaware) Common Stock is 1.310
When was Actinium Pharmaceuticals, Inc. (Delaware) Common Stock last traded?
The last trade of Actinium Pharmaceuticals, Inc. (Delaware) Common Stock was at 04/25/25 08:00 PM ET
What is the market capitalization of Actinium Pharmaceuticals, Inc. (Delaware) Common Stock?
The market capitalization of Actinium Pharmaceuticals, Inc. (Delaware) Common Stock is 27.94M
How many shares of Actinium Pharmaceuticals, Inc. (Delaware) Common Stock are outstanding?
Actinium Pharmaceuticals, Inc. (Delaware) Common Stock has 28M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.